Addex Therapeutics (ADXN) Non-Current Assets (2018 - 2026)
Addex Therapeutics (ADXN) posted Non-Current Assets of $4.6 million for Q1 2026, down 22.22% sequentially from $5.9 million in Q4 2025, and down 34.82% YoY from $7.0 million in Q1 2025.
Addex Therapeutics (ADXN) Non-Current Assets (2018 - 2026) Analysis & Trends
Addex Therapeutics has reported Non-Current Assets for 9 years, with the latest figure at $4.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 34.82% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (down 34.82% YoY) and the FY2025 annual result came in at $5.6 million, down 30.36% from the prior year.
- Non-Current Assets eased to $4.6 million in Q1 2026 per ADXN's latest filing, from $5.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $10.0 million in Q2 2024 and troughed at $45125.0 in Q1 2024.
- A 5-year average of $3.6 million and a median of $562122.6 in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets slumped 89.01% in 2024, then soared 15397.26% in 2025.
- Over 5 years, Non-Current Assets stood at $470316.3 in 2022, then dropped by 2.37% to $459148.9 in 2023, then surged by 1674.36% to $8.1 million in 2024, then retreated by 28.06% to $5.9 million in 2025, then fell by 22.22% to $4.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $4.6 million, $5.9 million, and $6.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | 4.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 5.86 Mn |
| Sep 30, 2025 | 6.21 Mn |
| Jun 30, 2025 | 7.06 Mn |
| Mar 31, 2025 | 6.99 Mn |
| Dec 31, 2024 | 8.15 Mn |
| Sep 30, 2024 | 9.34 Mn |
| Jun 30, 2024 | 9.96 Mn |
| Mar 31, 2024 | 45,124.99 |
| Dec 31, 2023 | 459,148.93 |
| Sep 30, 2023 | 447,645.20 |
| Jun 30, 2023 | 341,278.85 |
| Mar 31, 2023 | 410,602.84 |
| Dec 31, 2022 | 470,316.31 |
| Sep 30, 2022 | 560,141.66 |
| Jun 30, 2022 | 452,605.42 |
| Mar 31, 2022 | 562,122.64 |
| Dec 31, 2021 | 650,709.93 |
| Sep 30, 2021 | 679,623.10 |
| Jun 30, 2021 | 582,940.32 |